Several biotech startups, including Marea Therapeutics, have secured substantial funding to develop innovative treatments for cardiometabolic diseases and cancer. Marea Therapeutics, with $190 million in funding, aims to target lingering cholesterol to reduce heart disease risks.
A 10-person startup called Marea has raised $190 million to help develop a drug to lower a type of cholesterol and a new way of attacking cardiovascular disease. https://t.co/smKMPKI0rt
How this biotech startup team is hunting down the world's No. 1 killer. https://t.co/ptiiX3xgzm
How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease https://t.co/FEjPFzFYpe @matthewherper writes about Marea, a new biotech company founded by @ethanjweiss
How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease. @matthewherper has the story: https://t.co/tflIwJ7hYD
Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases https://t.co/qMBcTljJQu https://t.co/HQvqc7HkFX
Introducing Marea - a clinical-stage biotech on a mission to leverage large-scale human genetics and adipose biology to revolutionize the treatment of #cardiometabolic diseases. Learn more: https://t.co/z0DoJKgWfq https://t.co/DUPHJp6E3B
Company News: After exiting stealth mode with $190M today, @Marea_tx co-founder @ethanjweiss describes ANGPTL4 as a cardiometabolic target and more. Full video: https://t.co/Ls1WSCssqn https://t.co/eCZ3Pq1JOY
Lingering cholesterol can keep heart risk high. Marea Therapeutics has $190M to target it. https://t.co/XvD4agq7C5 by @gwendolynawu #biotech #startups $NVS
Sandbox alum team @leuko developed a noninvasive way to monitor cancer patients’ health during chemotherapy that will also help physicians make more informed care decisions. Learn more here: https://t.co/Edt7LRqIQ5